Shopping Cart
- Remove All
- Your shopping cart is currently empty
Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3 antigen on T-cells while exhibiting low Fc receptor binding activity to minimize activation-induced cytotoxicity. this unique design potentially suppresses the body's immune response through the modulation of T-cell function, and Visilizumab can be used in studies about the treatment of ulcerative colitis and Crohn's disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $328 | In Stock | |
5 mg | $993 | In Stock | |
10 mg | $1,330 | In Stock | |
25 mg | $1,980 | In Stock | |
50 mg | $2,680 | In Stock |
Description | Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3 antigen on T-cells while exhibiting low Fc receptor binding activity to minimize activation-induced cytotoxicity. this unique design potentially suppresses the body's immune response through the modulation of T-cell function, and Visilizumab can be used in studies about the treatment of ulcerative colitis and Crohn's disease. |
In vitro | Methods: Visilizumab (1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10,000 ng/mL, 2-48 hours (samples were taken and analyzed at 2, 4, 20, 24, and 48 hours)) was used to treat lamina propria T cells and observe their cell growth. Results: Visilizumab was able to induce dose- and time-dependent apoptosis of lamina propria T cells. [1] |
Synonyms | HuM291, Anti-Human CD3E Recombinant Antibody |
Cas No. | 219716-33-3 |
Color | Transparent |
Appearance | Liquid |
Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.